![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1722729
Åõ¼®±â ½ÃÀå º¸°í¼ : À¯Çüº°, »ç¿ë À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°(2025-2033³â)Dialyzer Market Report by Type (High-Flux Dialyzer, Low-Flux Dialyzer), Usage Type (Disposable, Reusable), End User (Hospitals and Clinics, Ambulatory Surgical Centers, Home Care Settings, Dialysis Centers), and Region 2025-2033 |
¼¼°è Åõ¼®±â ½ÃÀå ±Ô¸ð´Â 2024³â 38¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2033³â¿¡´Â 57¾ï ´Þ·¯¿¡ ´ÞÇϰí, 2025-2033³â ¿¬Æò±Õ ¼ºÀå·ü(CAGR)Àº 4.37%¸¦ º¸ÀÏ °ÍÀ¸·Î Àü¸ÁÇϰí ÀÖ½À´Ï´Ù. ÀçÅà Åõ¼®¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡, ´ç´¢º´, °íÇ÷¾Ð µî ½ÅÀå ÁúȯÀ» À¯¹ßÇÏ´Â »ýȰ½À°üº´ÀÇ À¯º´·ü Áõ°¡, Á¤ºÎÀÇ Áö¿ø Á¤Ã¥ ¹× »óȯ ÇÁ·Î±×·¥ ½ÃÇà Áõ°¡ µîÀÌ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
Àΰø ½ÅÀåÀ̶ó°íµµ ºÒ¸®´Â Åõ¼®±â´Â ¾ãÀº ¼¶À¯Áú Àç·á¸¦ »ç¿ëÇÏ¿© ¹ÝÅõ°ú¼º ¸·À» Çü¼ºÇϰí ÀÛÀº ÀÔÀÚ³ª ¾×ü¸¦ Åë°ú½ÃŰ´Â ÀåÄ¡ÀÔ´Ï´Ù. ½ÅÀåÀÌ Á¦´ë·Î ÀÛµ¿ÇÏÁö ¾ÊÀ» ¶§ Ç÷¾×¿¡¼ °úµµÇÑ ¼öºÐ°ú ³ëÆó¹°À» Á¦°ÅÇÏ°í ¿°ºÐ ¹× Áßµ¶ÀÇ ÃàÀûÀ» ¹æÁöÇÏ´Â ºñ¿ë È¿À²ÀûÀÎ ¼Ö·ç¼ÇÀÔ´Ï´Ù. Æó±â¹° ó¸® °¨¼Ò, ȯ°æ ¿µÇâ ÃÖ¼ÒÈ, ù »ç¿ë ÁõÈıº ºóµµ °¨¼Ò, »ýü ÀûÇÕ¼º Çâ»ó µî ¿©·¯ °¡Áö ÀÌÁ¡ÀÌ ÀÖ½À´Ï´Ù. ±× °á°ú, Àü ¼¼°è ½Ã¼³ Åõ¼® ¹× ÀçÅà Åõ¼®¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù.
ÇöÀç °³ÀÎµé »çÀÌ¿¡¼ ´ç´¢º´, °íÇ÷¾Ð, ½ÉÀ庴, ¸»±â½ÅºÎÀü(ESRD)ÀÇ À¯º´·üÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ´Â Àü ¼¼°è ³ëÀÎ Àα¸ Áõ°¡¿Í ÇÔ²² ½ÃÀåÀ» À̲ô´Â Áß¿äÇÑ ¿äÀÎ Áß Çϳª°¡ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °¢±¹ Á¤ºÎÀÇ Åõ¼® Á¦Ç° ¹× Åõ¼® ¼ºñ½º °³¼±À» À§ÇÑ ÀÚ±Ý Áö¿ø Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Àü ¼¼°èÀûÀ¸·Î ÀÌ½Ä¿ë ½ÅÀåÀÌ ºÎÁ·ÇÏ¿© ÁÖ¿ä ½ÃÀå ±â¾÷¿¡°Ô À¯¸®ÇÑ ¼ºÀå ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ ¿Ü¿¡µµ Åõ¼® ¼¾ÅÍ¿¡¼ ÈÆ·ÃµÈ ÀÇ·áÁøÀ» ÀÌ¿ëÇÒ ¼ö ÀÖ°í ȯÀÚ¿¡°Ô ´õ ³ªÀº ¼ºñ½º¸¦ Á¦°øÇÒ ¼ö ÀÖ´Ù´Â Á¡µµ ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¸¸¼º ½ÅÀå Áúȯ Ä¡·á¸¦ À§ÇÑ »õ·Î¿î Á¦Ç°ÀÇ »ç¿ëÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Àü ¼¼°è Åõ¼®±â ¼ö¿ä¸¦ ÀÚ±ØÇϰí ÀÖ½À´Ï´Ù. À̿ʹ º°µµ·Î, Ç÷¾× Åõ¼® Áß Å« Å©±âÀÇ µ¶¼Ò ºÐÀÚ¸¦ Á¦°ÅÇϱâ À§ÇÑ °í À¯·® Åõ¼®±âÀÇ ³ôÀº È¿À²¼ºµµ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ±âŸ ¼ºÀå ÃËÁø¿äÀÎÀ¸·Î´Â ÇコÄÉ¾î »ê¾÷ÀÇ È®´ë, ÀÇ·á °ü±¤ Áõ°¡, ÀÇ·á º¸Çè Á¤Ã¥ Áõ°¡, Á¦Ç° Á¦Á¶ °øÁ¤ÀÇ ±â¼ú ¹ßÀü µîÀÌ ÀÖ½À´Ï´Ù.
The global dialyzer market size reached USD 3.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 5.7 Billion by 2033, exhibiting a growth rate (CAGR) of 4.37% during 2025-2033. The growing preferences for home dialysis, rising prevalence of lifestyle-related diseases, such as diabetes and hypertension, that often lead to kidney problems, and increasing implementation of supportive government policies and reimbursement programs are some of the factors impelling the market growth.
A dialyzer, also known as an artificial kidney, is an apparatus manufactured using a thin and fibrous material to form a semipermeable membrane, which allows smaller particles and liquids to pass through. It is a cost-effective solution that removes excess fluids and wastes from the blood when kidneys are unable to function properly and prevents accumulation of salt and poisoning. It offers several advantages, such as less waste disposal, minimizing environmental impact, decreasing the frequency of first use syndrome, and improving biocompatibility. As a result, it finds extensive applications in in-center dialysis and home dialysis across the globe.
At present, there is a rise in the prevalence of diabetes, hypertension, heart disease, and end-stage renal diseases (ESRD) among individuals. This, along with the growing geriatric population around the world, represents one of the key factors driving the market. Moreover, the increasing funding on improving dialysis products and services by governments of several countries is propelling the growth of the market. In addition, the shortage of kidneys for transplantation across the globe is offering lucrative growth opportunities to key market players. Besides this, the availability of trained medical staff in dialysis centers that provide better services to the patient is positively influencing the market. Additionally, the rising utilization of novel products to treat chronic kidney conditions is catalyzing the demand for dialyzers worldwide. Apart from this, the higher efficiency of high-flux dialyzers to remove large size toxin molecules during the hemodialysis is bolstering the growth of the market. Other growth-inducing factors are the expanding healthcare industry, rising medical tourism, increasing reimbursement policies and technological advancements in the product production process.
The competitive landscape of the industry has also been examined along with the profiles of the key players being Asahi Kasei Corporation, B. Braun Melsungen AG, Baxter International Inc., Browndove Healthcare (P) Ltd., Cantel Medical Corporation (Steris plc), Dialife SA, Farmasol, Fresenius Medical Care AG & Co. KGaA, Medica S.p.A., Medtronic plc, Nikkiso Co. Ltd., Nipro Corporation, Shandong Weigao Group Medical Polymer Co. Ltd. and Toray Industries Inc.